BYM338 (Bimagrumab)
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sporadic Inclusion Body Myositis (sIBM)
Conditions
Sporadic Inclusion Body Myositis (sIBM)
Trial Timeline
Mar 11, 2014 → Aug 23, 2016
NCT ID
NCT02250443About BYM338 (Bimagrumab)
BYM338 (Bimagrumab) is a phase 2/3 stage product being developed by Novartis for Sporadic Inclusion Body Myositis (sIBM). The current trial status is completed. This product is registered under clinical trial identifier NCT02250443. Target conditions include Sporadic Inclusion Body Myositis (sIBM).
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02250443 | Phase 2/3 | Completed |
Competing Products
7 competing products in Sporadic Inclusion Body Myositis (sIBM)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bimagrumab + Placebo | Novartis | Phase 3 | 77 |
| BYM338/bimagrumab + Placebo | Novartis | Phase 2/3 | 65 |
| Everolimus | Novartis | Phase 2 | 52 |
| BYM338 + Placebo | Novartis | Phase 2 | 52 |
| LDE225 0.75% + Vehicle | Novartis | Phase 2 | 52 |
| Vandetanib 300 mg | Sanofi | Pre-clinical | 22 |
| REGN2477+REGN1033 + Matching placebo | Regeneron Pharmaceuticals | Phase 2 | 51 |